Tirzepatide ODT 5mg

Tirzepatide ODT 5 mg is a compounded orally disintegrating formulation of tirzepatide designed to provide a needle-free alternative to injectable therapy. Tirzepatide functions as a dual incretin agonist, activating both GLP-1 and GIP receptors to improve glycemic control, enhance insulin secretion, suppress glucagon release, and reduce appetite. These combined effects contribute to clinically significant weight loss and improved metabolic outcomes in patients with obesity or type 2 diabetes. The 5 mg ODT dose is generally considered a higher or advanced dosing level, often used after titration from lower doses such as 3 mg or 4 mg, depending on patient tolerance and treatment goals. It is typically taken once daily and dissolves in the mouth for transmucosal absorption. However, unlike FDA-approved injectable tirzepatide, compounded ODT formulations have not undergone the same level of regulatory review, and their absorption and bioavailability may vary between individuals. Common side effects are consistent with GLP-1 receptor agonists and include nausea, decreased appetite, constipation, and fatigue. Due to variability in compounded formulations, use should be guided by a licensed healthcare provider. Citation: U.S. Food and Drug Administration; National Center for Biotechnology Information